来自金黄色葡萄球菌的免疫调节剂在三阴性乳腺癌免疫治疗启动中的表征

Immunotherapy, specifically immune checkpoint blockade (ICB), has revolutionized the treatment paradigm of triple-negative breast cancers (TNBCs).

However, a subset of TNBCs devoid of tumor-infiltrating T cells (TILs) or PD-L1 expression generally has a poor response to immunotherapy. In this study, we aimed to sensitize TNBCs to ICB by harnessing the immunomodulating potential of S. aureus, a breast-resident bacterium.

We show that intratumoral injection of spent culture media from S. aureus recruits TILs and suppresses tumor growth in a preclinical TNBC model.

We further demonstrate that α-hemolysin (HLA), an S. aureus-produced molecule, increases the levels of CD8 + T cells and PD-L1 expression in tumors, delays tumor growth, and triggers tumor necrosis.

Mechanistically, while tumor cells treated with HLA display Gasdermin E (GSDME) cleavage and a cellular phenotype resembling pyroptosis, splenic T cells incubated with HLA lead to selective expansion of CD8 + T cells.

Notably, intratumoral HLA injection prior to ICB augments the therapeutic efficacy compared to ICB alone.

This study uncovers novel immunomodulatory properties of HLA and suggests that intratumoral administration of HLA could be a potential priming strategy to expand the population of TNBC patients who may respond to ICB.